AceLink Therapeutics Inc., a clinical stage biopharmaceutical company developing transformative therapies for kidney diseases, announced today that it has established AceLink Therapeutics China subsidiary at Suzhou Industry Park, China. Dr. Jerry Shen, Chairman, CEO and co-founder of the company said, “we are very excited to have our China company established. This new entity will allow us to interact closely with our local partners, conduct clinical trials in China and recruit local talents to advance our research and development programs. Our mission is to bring products to China market to help Chinese patients with unmet medical needs and to bring the drug candidates developed in China to the global market”.

“The official launching of AceLink’s China office is an important and exciting milestone. AceLink China will play a key role in facilitating collaboration, strengthening partnership, streamlining communication, accelerating drug research and clinical development globally, and delivering innovative therapeutics to patients in need.” said Dr. Jianhong Zheng, General Manager of AceLink Therapeutics, China.

About AceLink Therapeutics, Inc.

Founded in 2018, AceLink Therapeutics is an innovative biopharma startup focusing on developing safe and effective medicines to address kidney diseases with high unmet needs. The company’s initial focus is to develop novel therapeutics for genetically associated kidney disorders, such as Fabry disease. For more information, please visit www.acelinktherapeutics.com.

Contact Information:

Jerry Shen, Ph.D.

CEO and President

Phone: (925) 262-3145

Email: [email protected]

Jianhong Zheng, Ph.D.

General Manager, 艾司林科（苏州）生物医药有限公司

Phone: 15821372802

Email: [email protected]